Sode Jacob, Vogel Ulla, Bank Steffen, Andersen Paal Skytt, Thomsen Marianne Kragh, Hetland Merete Lund, Locht Henning, Heegaard Niels H H, Andersen Vibeke
Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark; Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
National Research Centre for the Working Environment, Copenhagen, Denmark.
PLoS One. 2014 Jun 26;9(6):e100361. doi: 10.1371/journal.pone.0100361. eCollection 2014.
Many patients with rheumatoid arthritis (RA) benefit from tumor necrosis factor-α blocking treatment (anti-TNF), but about one third do not respond. The objective of this study was to replicate and extend previously found associations between anti-TNF treatment response and genetic variation in the TNF-, NF-κB- and pattern recognition receptor signalling pathways.
Forty-one single nucleotide polymorphisms (SNPs), including 34 functional, in 28 genes involved in inflammatory pathways were assessed in 538 anti-TNF naive Danish RA patients with clinical data. Multivariable logistic regression analyses were performed to test associations between genotypes and treatment response at 3-6 months using the European League Against Rheumatism (EULAR) response criterion. American College of Rheumatology treatment response (ACR50) and relative change in 28-joint disease activity score (relDAS28) were used as secondary outcomes. Subgroup analyses were stratified according to smoking status, type of anti-TNF drug and IgM-Rheumatoid Factor (IgM-RF) status. False discovery rate (FDR) controlling was used to adjust for multiple testing.
Statistically significant associations with EULAR response were found for two SNPs in NLRP3(rs4612666) (OR (odds ratio) for good/moderate response = 0.64 (95% confidence interval: 0.44-0.95), p = 0.025, q = 0.95) and INFG(rs2430561) (OR = 0.40 (0.21-0.76), p = 0.005, q = 0.18) and among IgM-RF positive patients for TNFRS1A(rs4149570) (0.59 (0.36-0.98), p = 0.040, q = 0.76). Current smokers who carried the NLRP3(rs4612666) variant allele were less likely to benefit from anti-TNF treatment (OR = 0.24 (0.10-0.56), p = 0.001, q = 0.04).
In a population of Danish RA patients, we confirm the NLRP3 gene as associated with EULAR anti-TNF response as previously reported. The NLRP3 variant (T) allele is associated with lower treatment response, in particular among current smokers. Furthermore, we find that a functional polymorphism in the interferon-γ gene is associated with anti-TNF response. All findings should be tested by replication in independent validation cohorts and augmented by assessing cytokine levels and activities of the relevant gene products.
许多类风湿关节炎(RA)患者受益于肿瘤坏死因子-α阻断治疗(抗TNF),但约三分之一的患者无反应。本研究的目的是重复并扩展先前发现的抗TNF治疗反应与TNF-、NF-κB和模式识别受体信号通路基因变异之间的关联。
在538例未接受过抗TNF治疗且有临床数据的丹麦RA患者中,评估了参与炎症通路的28个基因中的41个单核苷酸多态性(SNP),包括34个功能性SNP。使用欧洲抗风湿病联盟(EULAR)反应标准,进行多变量逻辑回归分析,以测试3至6个月时基因型与治疗反应之间的关联。美国风湿病学会治疗反应(ACR50)和28关节疾病活动评分的相对变化(relDAS28)用作次要结果。根据吸烟状况、抗TNF药物类型和IgM类风湿因子(IgM-RF)状态进行亚组分析。采用错误发现率(FDR)控制方法对多重检验进行校正。
在NLRP3基因的两个SNP(rs4612666)中发现与EULAR反应有统计学显著关联(良好/中度反应的优势比(OR)=0.64(95%置信区间:0.44-0.95),p=0.025,q=0.95)和INFG基因的SNP(rs2430561)(OR=0.40(0.21-0.76),p=0.005,q=0.18),在IgM-RF阳性患者中,TNFRS1A基因的SNP(rs4149570)与EULAR反应有统计学显著关联(OR=0.59(0.36-0.98),p=0.040,q=0.76)。携带NLRP3基因(rs4612666)变异等位基因的当前吸烟者从抗TNF治疗中获益的可能性较小(OR=0.24(0.10-0.56),p=0.001,q=0.04)。
在丹麦RA患者群体中,我们证实NLRP3基因与EULAR抗TNF反应相关,如先前报道。NLRP3基因变异(T)等位基因与较低的治疗反应相关,尤其是在当前吸烟者中。此外,我们发现干扰素-γ基因中的一个功能性多态性与抗TNF反应相关。所有发现均应在独立验证队列中进行重复验证,并通过评估细胞因子水平和相关基因产物的活性加以补充。